CURX Key Statistics, Chart & Performance
The current stock price of CURX is 0.3997 USD. In the past month the price decreased by -13.99%.
CURX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About CURX
Company Profile
Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
Company Info
CURANEX PHARMACEUTICALS INC
2 Jericho Plaza, Suite101B
Jericho NEW YORK US
Employees: 0
Phone: 17186736078
CURANEX PHARMACEUTICALS INC / CURX FAQ
What does CURANEX PHARMACEUTICALS INC do?
Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
What is the current price of CURX stock?
The current stock price of CURX is 0.3997 USD. The price decreased by -6.5% in the last trading session.
What is the dividend status of CURANEX PHARMACEUTICALS INC?
CURX does not pay a dividend.
What is the ChartMill rating of CURANEX PHARMACEUTICALS INC stock?
CURX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy CURX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CURX.
What is the Short Interest ratio of CURANEX PHARMACEUTICALS INC (CURX) stock?
The outstanding short interest for CURANEX PHARMACEUTICALS INC (CURX) is 0.89% of its float.
CURX Technical Analysis
CURX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CURX. CURX has a great financial health rating, but its profitability evaluates not so good.
CURX Financial Highlights
Over the last trailing twelve months CURX reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS decreased by -1757.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.45% | ||
| ROE | -10.59% | ||
| Debt/Equity | 0 |